A Chapel Hill-based biotechnology company has raised $4.1 million in a private equity offering, according to a filing Thursday with the Securities and Exchange Commission.
BioFluidica Inc. raised the money from nine investors, according to the filing. It raised $2 million in 2016.
The company’s diagnostic platform provides a non-invasive procedure that can be applied to many diseases where there is a need for improved diagnostics.
The platform has been validated for six different cancer types, stroke and infectious diseases.
Its founder is UNC-Chapel Hill biomedical engineering and chemistry professor Steven A. Soper, who is the company’s chief technology officer.
He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experiences in the CTC research area along with being the author of five patents currently licensed by BioFluidica.
BioFluidica’s Chief Executive Officer is Rolf Muller. Prior to joining BioFluidica, he was the co-founder and president of Biomatrica, which he developed into a leader in biopreservation technologies for diagnostic and health care companies.
Private companies similar to BioFluidica, which rely on a Reg D exemption, aren’t required to register securities offerings with the SEC, but instead they must file a Form D electronically with the SEC after they sell the securities.